GSK Experimental Drug Reduces Severe Asthma Attacks in Trial

  • 📰 BNNBloomberg
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 50%

Law Law Headlines News

Law Law Latest News,Law Law Headlines

An experimental drug from GSK Plc reduced asthma attacks in late-stage trials, paving the way for a treatment that the British drugmaker thinks could exceed £3 billion ($3.8 billion) in sales.

Korean Consumers Turn Pessimistic as Rates Stay High for LongerOil Dips as Geopolitical Tension Fails to Jolt Lackluster MarketAsian Stocks Look Mixed as Traders Await Nvidia: Markets WrapEther Jumps to Lead Crypto Rally on ETF Approval SpeculationGermany Warms to US Plan to Tap Frozen Russian Assets for Ukraine FundsJPMorgan’s Kolanovic Is Last Prominent Bear as Mike Wilson FoldsBluebay Sees India Bond Inclusion Spur Outflow From South Africa, Colombia AssetsSaudi King’s Health, Iran...

What you should knowFirst 2024 Canada carbon rebates will be deposited today for some CanadiansThe big benefits of adopting a debt-free lifestyleMost young adults think retiring by 65 is outdated: surveyMany Canadians still feeling squeezed even as debt worries ease: insolvency firmHow to avoid OAS clawbacks and other tax traps in retirementSurvey finds nearly half of Canadians feeling 'stuck at work'Time to shift that parked RRSP contribution into driveChinese Builder Vanke Takes On...

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 83. in LAW

Law Law Latest News, Law Law Headlines